Replies to post #12106 on NorthWest Biotherapeutics Inc (NWBO)

[BioInfo]

we are better off without buyout as if successful it will be one of a lifetime opportunity to make millions. Remember, NWBO heldoff on Prostate trial due to cash needed and pursued GBM trial instead and if successful would pay for everything. I also believe both DCVax L and Direct can be applied to Prostate without running major trials per NWBO's understanding as after approval all they need to do is label extension. folks? correct? doesnt phase 3 trial for prostate me become unnecessary? They are already hitting Direct to prostate patients. L is still waiting for GBM success.

[terry hallinan]

Evening, AngeloFoca.

Bayer buys into PhIII-ready prostate cancer drug with $68M upfront

Cheapskates.

Johnson & Johnson Strikes $365M Prostate Cancer Licensing Deal With Aduro BioTech

https://pevc.dowjones.com/Article?an=DJFVW00020140530ea5uqzmuc&cid=32135017&ctype=ts&ReturnUrl=https%3a%2f%2fpevc.dowjones.com%2fArticle%3fan%3dDJFVW00020140530ea5uqzmuc%26cid%3d32135017%26ctype%3dts

Something of a headscratcher. Aduro, a private biotech, has its main claim to fame an extraordinarily good cancer killer as an adjuvant but Aduro is a laggard albeit with some failed technology. J&J BTW is known for being a bum buyer and may have lived up to its reputation but there are always lots of unknowables.

Whatever the German regulators think they know about NWBO, it would seem they haven't told Bayer.

Best, Terry